C. Bentley

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Allan C. deCamp, J. Mullins, J. Kublin, 2021, The New England journal of medicine.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Allan C. deCamp, J. Kublin, J. Mascola, 2017, Statistical communications in infectious diseases.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

J. Kublin, D. Montefiori, N. Frahm, 2018, The lancet. HIV.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

M. Andrasik, J. Kublin, M. McElrath, 2021, The New England journal of medicine.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

S. Hammer, R. Gottardo, S. Buchbinder, 2017, The Journal of infectious diseases.

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men

J. Kublin, P. Gilbert, L. Corey, 2015, PloS one.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Holly Janes, David C Montefiori, Peter B Gilbert, 2013, The New England journal of medicine.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

J. Kublin, D. Montefiori, N. Frahm, 2020, PLoS medicine.